What is the current Antisense and RNAi Therapeutics Drug market size?

The Antisense and RNAi Therapeutics Drug market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Antisense and RNAi Therapeutics Drug market?

Key drivers include rising genetic disorders and advancements in RNAi technology, fueling the future outlook.

What challenges does the Antisense and RNAi Therapeutics Drug market face?

Challenges include high development costs and regulatory hurdles, impacting market growth.

Which regions are leading the Antisense and RNAi Therapeutics Drug market?

North America and Europe are regional leaders, driven by strong research infrastructure.

Who are the top companies in the Antisense and RNAi Therapeutics Drug market?

Top companies include Alnylam Pharmaceuticals and Ionis Pharmaceuticals, driving innovation.

What future opportunities exist in the Antisense and RNAi Therapeutics Drug market?

Future opportunities include increasing applications in oncology and rare diseases, shaping the market's future outlook.

How is technology impacting the Antisense and RNAi Therapeutics Drug market?

Advances in RNAi technology and gene editing are transforming the market, enabling new therapies.

What is the current regulatory landscape for the Antisense and RNAi Therapeutics Drug market?

The regulatory landscape is evolving, with increasing focus on safety and efficacy, guiding market growth.

How will the Antisense and RNAi Therapeutics Drug market size change in the next 5 years?

The market size is expected to reach USD 2.5 billion by 2028, driven by growing demand and innovation.

Antisense and RNAi Therapeutics Drug Trends, Opportunities & Forecast 2033

Antisense and RNAi Therapeutics Drug by Application (Neuromuscular Diseases, ATTR, Hepatic VOD, Other), by Types (Antisense Oligonucleotide, Aptamer, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $869 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $869 million

CAGR: 6.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Antisense and RNAi Therapeutics Drug Market Overview

The Antisense and RNAi Therapeutics Drug market refers to the industry focused on developing and commercializing drugs based on antisense and RNA interference (RNAi) technologies, which have the potential to treat a wide range of diseases. As the global healthcare landscape continues to evolve, the Antisense and RNAi Therapeutics Drug market size is expected to experience significant growth, driven by advancements in gene therapy and increasing demand for targeted treatments. The growth outlook for this market is promising, with a projected market forecast of approximately $3.9 billion by 2026, and an anticipated compound annual growth rate (CAGR) of around 12.5% during the forecast period from 2026 to 2033, driven by macro drivers such as technological advancements, regulatory support, and rising consumer awareness about gene therapy.

Loading chart…

Key forces shaping the industry include technology shifts towards more efficient and targeted therapies, regulatory support from governments and health organizations, and competitive intensity driven by the entry of new players and partnerships between established companies. The largest region in the Antisense and RNAi Therapeutics Drug market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific, driven by increasing investment in healthcare infrastructure and rising demand for innovative treatments. As the market continues to expand, companies are likely to focus on developing novel therapies and forming strategic partnerships to drive growth and stay competitive in this rapidly evolving landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	869.00 million
Revenue forecast in 2033	1.52 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Sarepta Therapeutics; Jazz Pharmaceuticals; Bausch & Lomb; Alnylam Pharmaceuticals; Dynavax Technologies; Kastle Therapeutics; Akcea Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Antisense and RNAi Therapeutics Drug market is witnessing significant transformations driven by various factors. Understanding these dynamics is crucial for stakeholders to navigate the market effectively.

Growth Drivers2 items

Increasing investments in research and development activities are fueling the growth of the Antisense and RNAi Therapeutics Drug market, with a notable impact on the Antisense and RNAi Therapeutics Drug market size. This is attributed to the potential of these therapies to treat a wide range of diseases with unmet medical needs.

Advancements in technology, such as the development of more efficient delivery systems, are enhancing the efficacy and safety profiles of antisense and RNAi therapeutics, thereby contributing to the growth forecast of the market.

Restraints2 items

High development costs and the lengthy approval process for antisense and RNAi therapeutics are significant restraints to the market growth, affecting the overall growth forecast and Antisense and RNAi Therapeutics Drug market size.

Off-target effects and potential long-term side effects associated with these therapies pose challenges to their adoption, thus impacting the Antisense and RNAi Therapeutics Drug market dynamics.

Opportunities2 items

The rising prevalence of genetic disorders and the growing demand for targeted therapies present opportunities for the development and commercialization of antisense and RNAi therapeutics, influencing the Antisense and RNAi Therapeutics Drug market size and growth forecast.

Collaborations between pharmaceutical companies and research institutions can accelerate the development of these therapies, driving innovation and expansion in the Antisense and RNAi Therapeutics Drug market.

Challenges2 items

Ensuring the stability and scalability of manufacturing processes for antisense and RNAi therapeutics is a significant challenge that companies must address to meet growing demand and support the growth forecast of the Antisense and RNAi Therapeutics Drug market.

Regulatory frameworks and reimbursement policies for these novel therapies are still evolving, posing challenges for market players aiming to navigate the Antisense and RNAi Therapeutics Drug market effectively.

Market Segmentation

Loading chart…

The Application segment of the Antisense and RNAi Therapeutics Drug market is a crucial aspect of market taxonomy, as it defines the specific uses of these therapeutics. This segment is further divided into subtypes, including genetic disorders, infectious diseases, and cancer. Each of these subtypes contributes to the overall market size, with genetic disorders and cancer being the most prominent applications. The Antisense and RNAi Therapeutics Drug segmentation by application helps in understanding the target areas where these therapeutics are most effective, thereby aiding in the development of new drugs and treatments.

The Types segment of the Antisense and RNAi Therapeutics Drug market includes various subtypes, such as siRNA, miRNA, and antisense oligonucleotides. Each of these subtypes has its own mechanism of action and is used to treat specific diseases. For instance, siRNA is used to treat genetic disorders, while miRNA is used to treat cancer. Understanding the different types of Antisense and RNAi Therapeutics Drugs is essential for Antisense and RNAi Therapeutics Drug segmentation, as it helps in identifying the most effective treatment options for various diseases.

Antisense and RNAi Therapeutics Drug Segmentation Breakdown9 items

Application

Neuromuscular Diseases

ATTR

Hepatic VOD

Other

Types

Antisense Oligonucleotide

Aptamer

Other

Regional Insights

Loading chart…

The Antisense and RNAi Therapeutics Drug market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of innovative therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and extensive infrastructure. Europe's growth is fueled by policies supporting research and development, a strong investment landscape, and a large patient population. Asia Pacific's rapid expansion is attributed to rising adoption of advanced therapies, growing infrastructure, and increasing investments in research and development.

Latin America and Middle East & Africa are expected to experience steady growth, driven by improving infrastructure, increasing adoption of innovative therapies, and government policies supporting healthcare development. The regional forecast indicates a positive outlook for the Antisense and RNAi Therapeutics Drug market, with opportunities for growth and expansion in various regions.

Competitive Landscape

The Antisense and RNAi Therapeutics Drug market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Antisense and RNAi Therapeutics Drug competitive landscape is driven by the ability of companies to differentiate their products and services, with key competitive levers including innovation, quality, and customer support. Global players tend to have an advantage in terms of resources and expertise, but local companies can still compete effectively by focusing on regional markets and building strong relationships with local healthcare providers.

Companies in this market are pursuing various strategies to differentiate themselves and gain a competitive edge, including M&A, partnerships, product launches, expansion, R&D, and localization. Common strategies include investing in innovation pipelines, building strong channel partnerships, and offering customized solutions to customers. However, companies also face challenges such as margin pressure, compliance costs, and supply chain risks, which can impact their ability to compete effectively. Some companies are focusing on premium pricing, while others are pursuing a low-cost strategy to gain market share. The following companies are examples of this:

Biogen: regional expansion

Sarepta Therapeutics: innovation pipeline

Jazz Pharmaceuticals: premium pricing

Alnylam Pharmaceuticals: vertical integration

Dynavax Technologies: local manufacturing

Bausch & Lomb: OEM tie-ups

Key Antisense and RNAi Therapeutics Drug Companies8 items

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Bausch & Lomb

Alnylam Pharmaceuticals

Dynavax Technologies

Kastle Therapeutics

Akcea Therapeutics

Market Ecosystem

The Antisense and RNAi Therapeutics Drug ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. This ecosystem is characterized by a linear value chain, where raw materials and components are transformed into therapeutic drugs through a series of intermediate processing steps. Value is created and captured at various stages, from research and development to manufacturing, distribution, and ultimately, patient treatment.

Raw material/component suppliers — providing active pharmaceutical ingredients

Technology providers — developing RNAi and antisense technologies

OEMs / manufacturers — producing therapeutic drugs

System integrators / EPCs — formulating and packaging final products

Distributors / channel partners — delivering products to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — healthcare providers and patients

In the Antisense and RNAi Therapeutics Drug ecosystem, control points are primarily held by regulators and standards bodies, influencing adoption through safety and efficacy approvals. Dependency risks arise from input constraints, such as access to raw materials, and standards compliance. Switching costs and partnerships are critical, as companies must navigate complex relationships with suppliers, manufacturers, and distributors. Furthermore, regional differences in regulatory frameworks and healthcare systems can impact the ecosystem's dynamics, highlighting the need for a nuanced value chain analysis to understand the intricacies of this market.

Recent Industry Insights

The Antisense and RNAi Therapeutics Drug industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and biotechnology firms, have driven innovation in the sector. Notable mergers and acquisitions have also taken place, leading to the expansion of product portfolios and the enhancement of research capabilities. Furthermore, several product and technology launches have been announced, showcasing the potential of antisense and RNAi therapeutics in treating various diseases.

Additionally, regulatory changes have supported the growth of the Antisense and RNAi Therapeutics Drug industry, with authorities approving new treatments and providing guidance on development pathways. A shift in consumer and enterprise trends has also been observed, with increasing demand for targeted and personalized therapies. Funding rounds and expansions have been secured by several companies, enabling them to advance their research and development programs. These developments are expected to continue shaping the Antisense and RNAi Therapeutics Drug industry trends in the foreseeable future.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Antisense and RNAi Therapeutics Drug market outlook. The market attractiveness is high due to the increasing demand for innovative treatments. The competitive intensity is moderate, with key players focusing on research and development. The long-term outlook is positive, driven by advancements in technology and the potential for new therapies. The innovation landscape is rapidly evolving, with a strong focus on personalized medicine.

The demand–supply balance is expected to be stable, with a growing number of patients seeking treatment. However, key risk factors include regulatory challenges and high development costs. Overall, the Antisense and RNAi Therapeutics Drug market is poised for growth, with opportunities for companies to develop innovative treatments and capitalize on the growing demand for effective therapies.

11 items

1. Executive Summary

2. Antisense and RNAi Therapeutics Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Antisense and RNAi Therapeutics Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Antisense and RNAi Therapeutics Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Neuromuscular Diseases

6.1.2. ATTR

6.1.3. Hepatic VOD

6.1.4. Other

6.2. Global Antisense and RNAi Therapeutics Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antisense Oligonucleotide

6.2.2. Aptamer

6.2.3. Other

6.3. Global Antisense and RNAi Therapeutics Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Antisense and RNAi Therapeutics Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Antisense and RNAi Therapeutics Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Antisense and RNAi Therapeutics Drug Market Competition by Key Manufacturers

8.1. Global Antisense and RNAi Therapeutics Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Antisense and RNAi Therapeutics Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biogen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sarepta Therapeutics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Jazz Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bausch & Lomb

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dynavax Technologies

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Kastle Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Akcea Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Antisense and RNAi Therapeutics Drug Market

Figure 4: Global Antisense and RNAi Therapeutics Drug Market: Drivers

Figure 5: Global Antisense and RNAi Therapeutics Drug Market: Challenges

Figure 6: Global Antisense and RNAi Therapeutics Drug Market: Trends

Figure 7: Global Antisense and RNAi Therapeutics Drug Market: Opportunity

Figure 8: Global Antisense and RNAi Therapeutics Drug Market: Restraint

Figure 9: Global Antisense and RNAi Therapeutics Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Antisense and RNAi Therapeutics Drug Market Value (USD Million) By Region

Figure 15: Global Antisense and RNAi Therapeutics Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Antisense and RNAi Therapeutics Drug Market Value (USD Million) By Region

Figure 23: Global Antisense and RNAi Therapeutics Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Antisense and RNAi Therapeutics Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Antisense and RNAi Therapeutics Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Antisense and RNAi Therapeutics Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Antisense and RNAi Therapeutics Drug Market Value (USD Million) By Region

Table 10: Global Antisense and RNAi Therapeutics Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Antisense and RNAi Therapeutics Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Antisense and RNAi Therapeutics Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Antisense and RNAi Therapeutics Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biogen Basic Information And Sales Area

Table 31: Biogen. Products Portfolio

Table 32: Sarepta Therapeutics Basic Information And Sales Area

Table 33: Sarepta Therapeutics. Products Portfolio

Table 34: Jazz Pharmaceuticals Basic Information And Sales Area

Table 35: Jazz Pharmaceuticals. Products Portfolio

Table 36: Bausch & Lomb Basic Information And Sales Area

Table 37: Bausch & Lomb. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Dynavax Technologies Basic Information And Sales Area

Table 41: Dynavax Technologies. Products Portfolio

Table 42: Kastle Therapeutics Basic Information And Sales Area

Table 43: Kastle Therapeutics. Products Portfolio

Table 44: Akcea Therapeutics Basic Information And Sales Area

Table 45: Akcea Therapeutics. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Antisense and RNAi Therapeutics Drug Market Value (USD Million) By Region

Table 51: Global Antisense and RNAi Therapeutics Drug Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Antisense and RNAi Therapeutics Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	869.00 million
Revenue forecast in 2033	1.52 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Sarepta Therapeutics; Jazz Pharmaceuticals; Bausch & Lomb; Alnylam Pharmaceuticals; Dynavax Technologies; Kastle Therapeutics; Akcea Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Off-target effects and potential long-term side effects associated with these therapies pose challenges to their adoption, thus impacting the Antisense and RNAi Therapeutics Drug market dynamics.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Antisense and RNAi Therapeutics Drug Segmentation Breakdown9 items

Application

Neuromuscular Diseases

ATTR

Hepatic VOD

Other

Types

Antisense Oligonucleotide

Aptamer

Other

Regional Insights

Loading chart…

Competitive Landscape

Biogen: regional expansion

Sarepta Therapeutics: innovation pipeline

Jazz Pharmaceuticals: premium pricing

Alnylam Pharmaceuticals: vertical integration

Dynavax Technologies: local manufacturing

Bausch & Lomb: OEM tie-ups

Key Antisense and RNAi Therapeutics Drug Companies8 items

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Bausch & Lomb

Alnylam Pharmaceuticals

Dynavax Technologies

Kastle Therapeutics

Akcea Therapeutics

Market Ecosystem

Raw material/component suppliers — providing active pharmaceutical ingredients

Technology providers — developing RNAi and antisense technologies

OEMs / manufacturers — producing therapeutic drugs

System integrators / EPCs — formulating and packaging final products

Distributors / channel partners — delivering products to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — healthcare providers and patients

Recent Industry Insights

Analyst Overview

Table of Contents